Código QR

Serum lipid profile in HCV patients treated with direct-acting antivirals: a systematic review and meta-analysis

Abstract Although direct-acting antivirals are very effective and safe drugs, several authors have reported the alteration of lipid profile during and after anti-HCV therapy suggesting a potential impact on the risk of cardiovascular events. We performed a systematic review and meta-analysis of obse...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Rosanna Villani, Francesca Di Cosimo, Antonino Davide Romano, Moris Sangineto, Gaetano Serviddio
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/882100244dc04735ad11b9611996c8ba
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

HIV tropism switch in archived DNA of HIV-HCV subjects successfully treated with direct-acting antivirals for HCV infection
por: Monica Basso, et al.
Publicado: (2021)

Decoupled Glucose and Lipid Metabolic Recovery after Viral Clearance in Direct-Acting Antiviral-Treated HCV Patients: A 3-Year Prospective Cohort Study
por: Heng Lee, et al.
Publicado: (2021)

‘Real-life’ experience with direct-acting antiviral agents for HCV after kidney transplant
por: Fabrizio Fabrizi, et al.
Publicado: (2021)

Effect of Successful Direct Acting Antivirals Therapy on Liver Stiffness in Patients with Chronic HCV Infection
por: Ibrahim Anam Ezzelregal, et al.
Publicado: (2020)

Possible correlation between increased serum free carnitine levels and increased skeletal muscle mass following HCV eradication by direct acting antivirals
por: Yoshimasa Tokuchi, et al.
Publicado: (2021)

Identification of HCV Resistant Variants against Direct Acting Antivirals in Plasma and Liver of Treatment Naïve Patients
por: V. Stalin Raj, et al.
Publicado: (2017)

CHALLENGES AND PERSPECTIVES IN HEPATITIS C VIRUS (HCV) RESEARCH IN AN ERA OF DIRECT ACTING ANTIVIRAL (DAA) THERAPY
por: A. Budkowska
Publicado: (2018)

Assessment of Left Ventricular Systolic Function by Speckle Tracking in Diabetic Patients Receiving Direct Acting Antiviral Drugs for Chronic HCV
por: Wael Hassib, et al.
Publicado: (2021)

L3 Skeletal Muscle Index Dynamics in Patients with HCV-Related Compensated Cirrhosis Following Sustained Virological Response after Direct Acting Antiviral Treatment
por: Florin Mihai, et al.
Publicado: (2021)

The efficacy of direct-acting antiviral therapy in patients with chronic hepatitis C
por: Irina RUSU, et al.
Publicado: (2020)

Baseline elevated serum angiopoietin-2 predicts long-term non-regression of liver fibrosis after direct-acting antiviral therapy for hepatitis C
por: Naoki Kawagishi, et al.
Publicado: (2021)

Hepatitis C virus cell-cell transmission and resistance to direct-acting antiviral agents.
por: Fei Xiao, et al.
Publicado: (2014)

Pharmacogenetics of hepatitis C: transition from interferon-based therapies to direct-acting antiviral agents
por: Kamal SM
Publicado: (2014)

Ultra-long-acting (XLA) antivirals for chronic viral hepatitis
por: Vicente Soriano, et al.
Publicado: (2022)

Efficacy of direct-acting antiviral therapy for hepatitis C viral infection. Real-life experience in Bahrain
por: Abdulla M, et al.
Publicado: (2019)

Effectiveness of direct-acting antiviral drugs against hepatitis C virus: predictive factors of response to the treatment
por: María E. Cárdaba-García, et al.
Publicado: (2021)

A viral dynamic model for treatment regimens with direct-acting antivirals for chronic hepatitis C infection.
por: Bambang S Adiwijaya, et al.
Publicado: (2012)

Liver stiffness regression after sustained virological response by direct-acting antivirals reduces the risk of outcomes
por: Juliana Piedade, et al.
Publicado: (2021)

Partial restoration of immune response in Hepatitis C patients after viral clearance by direct-acting antiviral therapy.
por: Meritxell Llorens-Revull, et al.
Publicado: (2021)

Real-world efficacy and safety of pangenotypic direct-acting antivirals against hepatitis C virus infection in Taiwan
por: Kao-Chi Chang, et al.
Publicado: (2021)

Metabolic syndrome in chronic hepatitis C infection: does it still matter in the era of directly acting antiviral therapy?
por: Lim TR
Publicado: (2014)

A Review on Extrahepatic Manifestations of Chronic Hepatitis C Virus Infection and the Impact of Direct-Acting Antiviral Therapy
por: Cesare Mazzaro, et al.
Publicado: (2021)

Comparison of liver biopsies before and after direct-acting antiviral therapy for hepatitis C and correlation with clinical outcome
por: Omar A. Saldarriaga, et al.
Publicado: (2021)

Impact of hepatitis C virus genotype-4 eradication following direct acting antivirals on liver stiffness measurement
por: Tag-Adeen M, et al.
Publicado: (2017)

DEVELOPMENT AND APPROBATION METHOD OF IDENTIFICATION MUTATIONS THE RESISTANCE OF THE HEPATITIS C VIRUS TO DIRECT-ACTING ANTIVIRAL AGENTS (DAAs)
por: D. E. Valutite, et al.
Publicado: (2018)

The Utility of ANTI-HCV S/CO Ratio, HCV-RNA and ALT Test in Predicting Viremia in ANTI-HCV Positive Patients
por: Tuğrul Himmetoğlu, et al.
Publicado: (2007)

Metabolism of phosphatidylinositol 4-kinase IIIα-dependent PI4P Is subverted by HCV and is targeted by a 4-anilino quinazoline with antiviral activity.
por: Annalisa Bianco, et al.
Publicado: (2012)

ASSOCIATION BEETWEEN IL-28β POLYMORPHISMS AND EFFECTIVENESS OF CONCOMITANT THERAPY OF HIV INFECTION IN PATIENTS WITH HCV/HIV CO-INFECTION DURING THE ANTIVIRAL THERAPY
por: E. S. Kovaleva
Publicado: (2014)

Inhibition of nuclear factor (erythroid-derived 2)-like 2 promotes hepatic progenitor cell activation and differentiation
por: Francesco Bellanti, et al.
Publicado: (2021)

EFFICACY OF FIRST AVAILABLE DIRECT-ACTING ANTIVIRAL AGENT IN TREATMENT OF CHRONIC HEPATITIS C; RESULTS FROM A SINGLE CENTRE IN PAKISTAN
por: Arif Qayyum Khan, et al.
Publicado: (2020)

Evaluation of MicroRNA-122 as a Biomarker for Chronic Hepatitis C Infection and as a Predictor for Treatment Response to Direct-Acting Antivirals
por: Elabd NS, et al.
Publicado: (2021)

Effect of different direct-acting antiviral regimens for treatment of nondiabetic hepatitis C virus–infected Egyptian patients on insulin resistance and sensitivity
por: Tarek Yosef, et al.
Publicado: (2021)

EFFICACY OF FIRST AVAILABLE DIRECT-ACTING ANTIVIRAL AGENT IN TREATMENT OF CHRONIC HEPATITIS C; RESULTS FROM A SINGLE CENTRE IN PAKISTAN
por: Arif Qayyum Khan, et al.
Publicado: (2020)

The nucleoside antiviral prodrug remdesivir in treating COVID-19 and beyond with interspecies significance
por: Daisy Yan, et al.
Publicado: (2021)

EFFICIENCY OF IMMUNOCORRECTION IN СHRONIC VIRAL HEPATITIS C PATIENTS TREATED BY ANTIVIRALS
por: L. P. Sklyar, et al.
Publicado: (2014)

Septin 9 induces lipid droplets growth by a phosphatidylinositol-5-phosphate and microtubule-dependent mechanism hijacked by HCV
por: Abdellah Akil, et al.
Publicado: (2016)

A systematic review and meta-analysis of the serum lipid profile in prediction of diabetic neuropathy
por: Zixin Cai, et al.
Publicado: (2021)

Link between serum lipid signature and prognostic factors in COVID-19 patients
por: Michele Dei Cas, et al.
Publicado: (2021)

Neutrophil gelatinase-associated lipocalin partly reflects the dynamic changes of renal function among chronic hepatitis C patients receiving direct-acting antivirals.
por: Yen-Chun Chen, et al.
Publicado: (2021)

Effects of Hepatitis C Virus Elimination by Direct-Acting Antiviral Agents on the Occurrence of Oral Lichen Planus and Periodontal Pathogen Load: A Preliminary Report
por: Yumiko Nagao, et al.
Publicado: (2021)